Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Harris

Psychiatry New Bern, NC Doctor of Osteopathy

NPI 1851716831 CMS profile 7522161

3252 Wellons Blvd, New Bern, NC 28562

Open in the dashboard

General payments

$17,106

597 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Harris of New Bern, NC is reported in the CMS Open Payments database as having received $17,106 across 597 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,388 180
2024 General $2,489 125
2023 General $2,364 141
2022 General $8,675 140
2021 General $189 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Harris
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Christopher Harris were reported at $3,388. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Christopher Harris Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $189 $143 $43–$576 $132
2022 $8,675 $153 $50–$590 $149
2023 $2,364 $170 $56–$651 $160
2024 $2,489 $179 $57–$673 $164
2025 $3,388 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $7,876 74 payments
  2. AbbVie, Inc. $1,337 66 payments
  3. Janssen Pharmaceuticals, Inc $1,210 46 payments
  4. Otsuka America Pharmaceutical, Inc. $1,035 56 payments
  5. ITI, Inc. $989 53 payments
  6. Teva Pharmaceuticals USA, Inc. $700 41 payments
  7. Lundbeck LLC $625 38 payments
  8. Vanda Pharmaceuticals Inc. $597 49 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $462 35 payments
  10. Neurocrine Biosciences, Inc. $440 25 payments
  11. Other $1,833 114 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,367 586 payments
  2. Consulting Fee $4,600 1 payment
  3. Travel and Lodging $2,003 4 payments
  4. Education $135 6 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $7,810 73 payments
  2. LYBALVI Cns $7,208 31 payments
  3. LYBALVI Cns $6,972 14 payments
  4. LYBALVI Cns $6,972 14 payments
  5. VRAYLAR $993 48 payments
  6. SPRAVATO $987 34 payments
  7. ARISTADA Cns $904 60 payments
  8. ARISTADA Cns $904 60 payments
  9. REXULTI $865 44 payments
  10. ARISTADA Cns $668 43 payments
  11. Other $8,860 574 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,852

Median for Psychiatry: 574

Drug cost

$241,149

Median for Psychiatry: $27,624

Branded share of claims

17.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 16 $126,006
Rexulti Brexpiprazole Brand 36 $49,117
Vraylar Cariprazine Hcl Brand 23 $29,046
Bupropion Xl Bupropion Hcl Brand 186 $3,499
Vilazodone Hcl Generic 16 $1,974
Quetiapine Fumarate Generic 109 $1,844
Trazodone Hcl Generic 242 $1,747
Lurasidone Hcl Generic 57 $1,640
Olanzapine Generic 89 $1,518
Venlafaxine Hcl Er Venlafaxine Hcl Brand 104 $1,507

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$82,531

Medicare's payments for the services billed

Medicare patients

186

Average age 69

Services billed

1,339

104 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 74%
Arthritis 55%
Diabetes 33%
Ischemic heart disease 31%
Chronic kidney disease 26%
COPD 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $275
  • Otsuka America Pharmaceutical, Inc. $58
$332 36 —
LYBALVI
  • Alkermes, Inc. $277
$277 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $230
$230 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $226
$226 — —
CAPLYTA
  • ITI, Inc. $210
$210 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

597 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record